Oncology Conference update

Highlights from ASCO 2025

Expert insights on the latest data 

Prof. Mark Socinski

Prof. Mark Socinski
Dr Elizabeth Smyth

Dr Elizabeth Smyth
Dr Paolo Tarantino

Dr Paolo Tarantino
Prof. Domenica Lorusso

Prof. Domenica Lorusso
Prof. Gerhardt Attard

Prof. Gerhardt Attard
Publication Date

Jun 2025

download Downloadable resources

Scroll down for updates on oncogene-addicted NSCLC, gastric, breast, gynecological, and prostate cancers.

 

 

Get expert opinion on the latest practice-changing data in BRAF-mutant and MSI-H/dMMR colorectal cancer here: Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC)

Prof. Mark Socinski talks to us about his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ASCO 2025. 

 

Prof. Socinski reviews data from the following key studies: 

  • SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant NSCLC who were pretreated but naȉve to HER2-targeted therapy or had not received any treatment for advanced disease. Loong H, et al. Abstract 8504, ASCO 2025
  • SOHO-02: Phase 3 trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. Le X, et al. Abstract TPS8648, ASCO 2025
  • SACHI: Savolitinib combined with osimertinib versus chemotherapy in EGFR-mutant and MET-amplification advanced NSCLC after disease progression on EGFR TKI: Results from a randomised Phase 3 SACHI study. Lu S, et al. Abstract LBA8505, ASCO 2025
  • OptiTROP-Lung03: Sacituzumab tirumotecan in patients with previously treated advanced EGFR-mutated NSCLC: Results from the randomised OptiTROP-Lung03 study. Zhang L, et al. Abstract 8507, ASCO 2025
  • HERTHENA-Lung02: Patritumab deruxtecan in resistant EGFR-mutated advanced NSCLC after a third-generation EGFR TKI: The Phase 3 HERTHENA-Lung02 study. Mok T, et al. Abstract 8506, ASCO 2025

 

Watch the short summary video and download the accompanying slides for a more detailed update.

 

Key clinical takeaways

  • SOHO-01/SOHO-02: Sevabertinib (BAY 2927088) produced meaningful and durable response rates in patients with advanced HER2-mutant NSCLC. The ongoing phase 3 trial, SOHO-02, will provide further data on the efficacy and safety of sevabertinib as 1st line therapy in patients with locally advanced or metastatic NSCLC with HER2-activating mutations
  • SACHI: The combination of savolitinib plus osimertinib demonstrated statistically significant and clinically meaningful improvement in PFS in MET-amplified NSCLC post first-line EGFR-TKI. This represents a significant therapeutic advancement for these patients and based on these results the combination therapy has been granted priority review by the China NMPA
  • OptiTROP-Lung03: Sacituzumab tirumotecan (Sac-TMT) improved PFS and OS compared to docetaxel in relapsed EGFR-mutant NSCLC post TKI and platinum-based chemotherapy, with a manageable safety profile. Sac-TMT has recently been approved by the China NMPA based on these results
  • HERTHENA-Lung02: Patritumab deruxtecan (HER3-DXd) more effective than platinum-based chemotherapy for PFS in relapsed EGFR-mutant NSCLC post 3rd generation TKI but no benefit in overall survival was observed. Patritumab deruxtecan biologics license application has been voluntarily withdrawn

 

  • Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2-directed NSCLC 

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Beigene, BMS, Cullinan, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis, OncoC4, Regeneron, Spectrum, Summit
Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
Endorsement
Exon20group ICAN international cancer advocacy network
Biomarker Collaborative
Lung Cancer Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved
download Downloadable resources

Dr Lizzy Smyth shares her views on practice-changing gastric cancer data as they emerge from the ASCO 2025 congress.

 

In this short video, Dr Lizzy Smyth reviews new findings from the MATTERHORN and DESTINY-Gastric04 studies and picks out her key clinical takeaways from both.

 

  • MATTERHORN: Event-free survival in MATTERHORN: A randomised, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy in resectable gastric/gastroesophageal junction cancer. Janjigian Y, et al. Abstract LBA5, ASCO 2025
  • DESTINY-Gastric04: Trastuzumab deruxtecan vs ramucirumab + paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary analysis of the randomised, Phase 3 DESTINY-Gastric04 study. Shitara K, et al. Abstract LBA4002, ASCO 2025

 

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amal Therapeutics, Aptitude Health, Amgen, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Viracta, Zymeworks
Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED
Supporter Acknowledgement
This educational programme is supported by COR2ED
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
DiCE
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
download Downloadable resources

 

 

Dr Paolo Tarantino joined us at ASCO to share expert insights on new breast cancer data from ASCO 2025.

 

See his video update and find out how he thinks these new data could impact clinical practice.

 

Dr Tarantino shares his thoughts on the SERENA-6, ASCENT-04/KEYNOTE-D19, and DESTINY-Breast09 studies:

 

  • SERENA-6: Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial. Turner N, et al. Abstract LBA4, ASCO 2025
  • ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab in previously untreated PD-L1–positive advanced triple-negative breast cancer: Primary results from the randomised Phase 3 ASCENT-04/KEYNOTE-D19 study. Tolaney S, et al. Abstract LBA109, ASCO 2025
  • DESTINY-Breast09: Trastuzumab deruxtecan + pertuzumab vs taxane + trastuzumab + pertuzumab for first-line treatment of patients with HER2+ advanced/metastatic breast cancer: Interim results from DESTINY-Breast09. Tolaney S, et al. Abstract LBA1008, ASCO 2025

Paolo Tarantino is a leading researcher in the field of breast cancer and drug development. He’s currently pursuing an advanced research fellowship at Dana Farber Cancer Institute and at Harvard Medical School (Boston, MA) and a PhD in clinical research at the University of Milan. His research focuses on the study of the HER2 oncoprotein, the biology of HER2-low breast tumors and the development of novel antibody-drug conjugates.

Dr Paolo Tarantino has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Tarantino decleares advisory role, speakers fees and/or research support from: AstraZeneca, Daiichi Sankyo, Lilly and Gilead.
Programme summary
  • clock Duration 3 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED
Supporter Acknowledgement
This educational programme is supported by COR2ED
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
Exon20group
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved
download Downloadable resources

Prof. Domenica Lorusso joins us at ASCO 2025 to give her insights into how new data presented at the meeting might impact clinical practice.

 

Prof. Lorusso reports on ovarian and cervical cancer data from the Phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18, ROSELLA, FIRST/ENGOT-OV44 and TRUST studies:

 

  • ENGOT-cx11/GOG-3047/KEYNOTE-A18: Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the Phase 3, randomised, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 Duska L, et al.  Abstract LBA5504, ASCO 2025
  • ROSELLA: A Phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer. Olawaiye A, et al. Abstract LBA5507, ASCO 2025
  • FIRST/ENGOT-OV44: A Phase 3 clinical trial of dostarlimab and niraparib in first-line advanced ovarian cancer. Hardy-Bessard A, et al. Abstract LBA5506, ASCO 2025
  • TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer. Mahner S, et al. Abstract LBA5500, ASCO 2025

Prof. Domenica "Ketta" Lorusso obtained her degree in Medicine and Surgery in 1995, her residency in Obstetrics and Gynecology in 1999 and her PhD in Obstetrics and Gynecology in 2003. She is currently Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome and responsible for clinical research at Fondazione Policlinico Gemelli IRCCS.

She is an active member of the European Network of Gynaecological Oncological Trial groups (ENGOT), where she leads the Gynecological Cancer Academy (since 2020). Dr Lorusso is a member of the Board of Directors of the Gynecologic Cancer InterGroup (GCIG), where she is the past chair of the Endometrial Cancer Committee and the Nomination and Meeting Committee. Currently, she is a member of the ESGO Council and scientific coordinator of the ESMO Gynaecological Cancers Congress. She is involved in preclinical and clinical research in gynaecological cancer, and she is the author of more than 250 papers on gynaecological cancers. Her work has hugely contributed to improving the quality of care and clinical outcome and to reducing the toxicity of treatments in women with advanced gynaecological malignancies.

Prof. Domenica Lorusso has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, GSK, Novartis, Clovis Oncology, AstraZeneca, Eisai, PharmaMar, ImmunoGen, Genmab
Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED
Supporter Acknowledgement
This educational programme is supported by COR2ED
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
OBSTETRICS & GYNECOLOGY CONNECT 

OBSTETRICS & GYNECOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Eisai Europe Ltd, Aspivix and Novo Nordisk.

Meet the experts Independent IME approved
download Downloadable resources

Prof. Gerhardt Attard joined us at ASCO after he presented new data in metastatic castration-sensitive prostate cancer from the Phase 3 AMPLITUDE study and a STAMPEDE Ancillary trial.

 

Watch here to get his expert insights into what these data mean for mCSPC management.

 

  • Phase 3 AMPLITUDE trial: Niraparib and abiraterone acetate plus prednisone for mCSPC patients with alterations in HRR genes. Attard G, et al. Abstract LBA5006, ASCO 2025
  • STAMPEDE Ancillary study: Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of ADT for metastatic prostate cancer: An ancillary study of the STAMPEDE trials.  Grist E, et al. Abstract 5003, ASCO 2025

 

 

Catch up on the latest practice-changing data in BRAF-mutant and MSI-H/dMMR colorectal cancer here: Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC) 

 

Prof. Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Prof. Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.

Prof. Gerhardt Attard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants or contracts from Astellas Pharma, Blue Earth Therapeutics, Janssen, Veracye and Novartis

 

Consulting fees from Amgen, AstraZeneca, Astellas Pharma, Bayer, Blue Earth Therapeutics, Janssen-Cilag, Merck & Co, Merck Sorono Ltd, Novartis, Pfizer, Veracyte.

 

Payment or honoraria from Astellas Pharma, Janssen, Astrazeneca, Sanofi, Sandoz.

 

Support for attending meetings/travel from Amgen, Astellas Pharma, Bayer, Janssen, Merck Sorono Ltd, Pfizer

 

On the Institute of Cancer Research Discoveries list of abiraterone acetate. Listed as inventor on docetaxel predictive, biomarker (Veracyte).

 

Listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons)

 

Commercial agreements with employer, UCL with Artera and Veracyte
Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by COR2ED
Supporter Acknowledgement
This educational programme is supported by COR2ED
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025: BRAF-mutant and MSI-H/dMMR colorectal cancer (CRC)

Expert opinion on the latest practice-changing data

Experts
Prof. Dominik Modest, Dr Sara Lonardi
  • clock 5 MIN
  • calendar Jun 2025
GI CONNECT GI NURSES CONNECT PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025
LUNG CONNECT PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Explore all programmes